0.17
-0.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Theriva Biologics
From its filings with the US Securities and Exchange Commission
Theriva Biologics is based in Rockville, Maryland and is incorporated in Nevada. Its shares trade on NYSE under the ticker TOVX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2011, it reported revenue of $0.
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L. (“VCN”, formerly named VCN Biosciences, S.L.), in March 2022, as described in more detail below (the “Acquisition”), we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer (“VIRAGE”), and a Phase 1 clinical study for the treatment of retinoblastoma, as well as various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 1993
- Employees
- 21
- Website
- therivabio.com ↗
- Head office
- 9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Jeffrey KrawsIndependent Chairman of the Board$180,250
- Mr. Steven ShallcrossChief Executive Officer, Chief Financial Officer, Director, since 2015$876,313
- Dr. John MonahanIndependent Director$77,750
- Mr. Jeffrey WolfIndependent Director$70,750
- Mr. Chris CalabreseIR Contact Officer, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Theriva Biologics employs 21 full-time staff members in the US.
- The firm advances an oncolytic adenovirus platform for intravenous delivery.
- VCN-01 is designed to replicate selectively within tumor cells.
Weaknesses
- The company has only 21 employees for its clinical stage operations.
- Theriva Biologics is headquartered in Rockville, Maryland, limiting local talent.
- SYN-004 requires degradation of beta-lactam antibiotics within the gastrointestinal tract.
Opportunities
- SYN-020 treats both local GI and systemic diseases effectively.
- The platform improves access of co-administered cancer therapies to tumors.
- Theriva Biologics promotes a robust anti-tumor response by patients.
Threats
- VCN-01 must degrade the tumor stroma barrier to succeed.
- SYN-004 targets used IV beta-lactam antibiotics in the GI tract.
- The company listed on 12 February 1993, facing long-term risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.